Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine time to disease progression of combination therapy
with capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continous
infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer
Phase:
Phase 3
Details
Lead Sponsor:
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)